Susquehanna International Group, LLP Tyme Technologies, Inc. Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Shares

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 15, 2022	SELL	$0.23 - $0.35 $156,364 - $237,946	-679,847 Reduced 97.91%	14,532 $4,000
Q1 2022 May 16, 2022	SELL	$0.28 - $0.68 $52,148 - $126,645	-186,244 Reduced 21.15%	694,379 $243,000
Q4 2021 Feb 14, 2022	BUY	$0.6 - $1.04 $13,766 - $23,861	22,944 Added 2.68%	880,623 $531,000
Q3 2021 Nov 15, 2021	BUY	$0.99 - $1.38 $523,569 - $729,824	528,858 Added 160.83%	857,679 $883,000
Q2 2021 Aug 11, 2021	BUY	$1.14 - $1.87 $130,259 - $213,671	114,263 Added 53.26%	328,821 $414,000
Q1 2021 May 17, 2021	BUY	$1.34 - $3.53 $252,256 - $664,526	188,251 Added 715.59%	214,558 $382,000
Q4 2020 Feb 16, 2021	SELL	$0.87 - $1.26 $6,480 - $9,385	-7,449 Reduced 22.07%	26,307 $32,000
Q3 2020 Nov 16, 2020	BUY	$0.93 - $1.35 $14,183 - $20,588	15,251 Added 82.42%	33,756 $33,000
Q2 2020 Aug 14, 2020	SELL	$0.97 - $1.7 $28,161 - $49,354	-29,032 Reduced 61.07%	18,505 $25,000
Q1 2020 May 15, 2020	SELL	$0.9 - $1.95 $3,981 - $8,626	-4,424 Reduced 8.51%	47,537 $52,000
Q4 2019 Feb 14, 2020	SELL	$1.0 - $1.49 $5,364 - $7,992	-5,364 Reduced 9.36%	51,961 $73,000
Q3 2019 Nov 14, 2019	BUY	$0.97 - $1.77 $10,353 - $18,892	10,674 Added 22.88%	57,325 $68,000
Q2 2019 Aug 16, 2019	BUY	$0.96 - $1.89 $26,810 - $52,783	27,928 Added 149.16%	46,651 $57,000
Q2 2019 Aug 14, 2019	BUY	$0.96 - $1.89 $17,974 - $35,386	18,723 New	18,723 $23,000
Q2 2018 Aug 14, 2018	SELL	$2.05 - $4.09 $200,584 - $400,190	-97,846 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$2.12 - $7.0 $207,433 - $684,922	97,846 New	97,846 $218,000

About TYME TECHNOLOGIES, INC.

Ticker TYME
Exchange NASDAQ
Shares Outstandng 172,207,008
Description
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...

More about TYME

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.